|1.||Morris, Timothy W: 14 articles (05/2015 - 05/2009)|
|2.||Comstock, Timothy L: 14 articles (05/2015 - 03/2009)|
|3.||Gearinger, Lynne S: 7 articles (12/2013 - 01/2011)|
|4.||Haas, Wolfgang: 7 articles (05/2012 - 05/2009)|
|5.||Paterno, Michael R: 7 articles (01/2011 - 03/2009)|
|6.||Usner, Dale W: 7 articles (01/2011 - 03/2009)|
|7.||Sanfilippo, Christine M: 5 articles (01/2015 - 06/2010)|
|8.||Ward, Keith W: 5 articles (10/2010 - 06/2007)|
|9.||Hesje, Christine K: 4 articles (05/2012 - 06/2010)|
|10.||Decory, Heleen H: 4 articles (01/2012 - 01/2010)|
10/01/2010 - "Taken together, these nonclinical data indicate that besifloxacin has a favorable ocular PK/PD profile, consistent with the reported clinical efficacy of besifloxacin in the treatment of bacterial conjunctivitis, and consistent with the profile needed for ocular surface sterilization."
05/01/2012 - "Treatment with besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days was effective and safe in adults and children with bacterial conjunctivitis. "
05/01/2012 - "Besifloxacin ophthalmic suspension 0.6% given thrice daily for 5 days is safe and effective in the treatment of patients with bacterial conjunctivitis. "
04/01/2010 - "Besifloxacin ophthalmic suspension 0.6% was shown to be safe and effective for the treatment of bacterial conjunctivitis in children and adolescents aged 1-17 years."
06/01/2015 - "This review provides an up-to-date summary of studies on causative pathogens in acute bacterial conjunctivitis; recent geographic trends in bacterial resistance among ocular pathogens, including that of methicillin-resistant Staphylococcus aureus; the efficacy of besifloxacin in preclinical and clinical studies; its safety; and the role of besifloxacin in combating resistant strains. "
04/01/2010 - "Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis."
10/01/2009 - "Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis."
03/01/2015 - "The study population included 142 patients treated with besifloxacin ophthalmic suspension 0.6% for bacterial keratitis in one or both eyes. "
03/01/2015 - "The objective of this study was to collect and evaluate retrospective safety information about the use of besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial keratitis. "
03/01/2015 - "Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study."
06/01/2007 - "BOL-303224-A displayed activity in in vitro antimicrobial efficacy studies and also demonstrated efficacy in an in vivo murine infection model. "
11/01/2008 - "The aim of this study was to determine the anti-inflammatory effects of besifloxacin, a novel fluoroquinolone under clinical evaluation for the treatment of ophthalmic infections, in human corneal epithelial cells (HCEpiC). "
01/01/2008 - "This study was conducted to evaluate the anti-inflammatory effects of besifloxacin, a novel fluoroquinolone under clinical evaluation for treatment of ophthalmic infections. "
08/01/2015 - "To present the clinical outcome of 3 cases of ocular surface infections by Mycobacterium chelonae treated with besifloxacin (0.6%, Besivance; Bausch & Lomb, Tampa, FL). "
08/01/2015 - "Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections."
01/01/2012 - "In this study, besifloxacin ophthalmic suspension 0.6% was well tolerated when used prophylactically to prevent postoperative endophthalmitis following sutureless cataract surgery."
06/01/2012 - "Besifloxacin has also been shown in preclinical animal studies to be potentially effective for the "off-label" treatment of infections following ocular surgery, prophylaxis of endophthalmitis, and the treatment of bacterial keratitis. "
06/01/2010 - "Besifloxacin is as effective as moxifloxacin and gatifloxacin in a rabbit model for topical prophylaxis and treatment of PRSP-induced endophthalmitis."
06/01/2010 - "Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis."
06/01/2011 - "To determine the concentrations of besifloxacin, moxifloxacin, and gatifloxacin in human aqueous humor after topical instillation of commercially available besifloxacin ophthalmic suspension 0.6%, moxifloxacin ophthalmic solution 0.5%, and gatifloxacin ophthalmic solution 0.3%, and to assess these concentrations relative to the minimum inhibitory concentration for 90% of strains (MIC(90)) for each drug against bacterial pathogens identified in recent cases of postoperative endophthalmitis. "
08/01/2015 - "Marked improvement of the conjunctivitis was noted after 3 weeks of treatment with topical besifloxacin. "
01/01/2010 - "Blurred vision, eye irritation and nonspecific conjunctivitis occurred in significantly fewer besifloxacin-treated patients than in vehicle-treated patients (p < or = 0.05). "
08/01/2015 - "Besifloxacin was used as an adjunct in 2 cases of keratitis and as the principal therapeutic agent in a case of nodular conjunctivitis. "
03/01/2010 - "Besifloxacin was generally well tolerated in these clinical trials, with the most common (> or =1.5%) ocular adverse events being nonspecific conjunctivitis (2.6%), blurred vision (2.1%), bacterial conjunctivitis (1.8%), and eye pain (1.5%). "
01/01/2010 - "In the integrated safety analysis of the three safety and efficacy studies, the most commonly reported ocular AEs in study eyes receiving besifloxacin ophthalmic suspension 0.6% were blurred vision (2.1%), eye pain (1.8%), eye irritation (1.4%), nonspecific conjunctivitis (1.2%) and eye pruritus (1.1%). "
|3.||Ophthalmic Solutions (Eye Drops)
|8.||7- ((3R)- aminohexahydro- 1H- azepin- 1- yl)- 8- chloro- 1- cyclopropyl- 6- fluoro- 1,4- dihydro- 4- oxo- 3- quinolinecarboxylic acid
|9.||DNA Topoisomerase IV (Topoisomerase IV)
|2.||Laser In Situ Keratomileusis (LASIK)